Effects of Renin—Angiotensin System Inhibition on Cardiac Hypertrophy and Fibrosis in Spontaneously Hypertensive Rats

  • Naoki Makino
  • Masahiro Sugano
  • Sachiyo Taguchi
Part of the Progress in Experimental Cardiology book series (PREC, volume 3)


The present study examined whether the inhibition of the renin-angiotensin system can change the cardiac remodeling process in spontaneously hypertensive rats (SHR). First, we administered AT1, blockade (losartan), AT2 blockade (PD123319), or ACE inhibitor (enalapril) to SHR from 10 to 20 weeks of age. Both losartan and enalapril reduced the arterial systolic blood pressure (BP) as well as the collagen concentration compared with the untreated SHR (U-SHR) to the level of Wistar Kyoto rats (WKY). Both agents also reduced both the left ventricular (LV) weight and the ratio of LV to body weight (BW) compared with the untreated SHR, although these measures were still larger than those of WKY. However, PD123319 was without effect. Second, to inhibit the plasma angiotensinogen (ATN) in SHR, we intravenously injected antisense oligodeoxynucleotides (ODNs) against rat ATN coupled to asialoglyco-protein carrier molecules into SHR (A-SHR) from 10 to 20 weeks via their tail veins twice a week. Both the ATN and Ang II concentrations in plasma decreased in A-SHR compared with those of the sense-treated SHR (S-SHR) or U-SHR. The BP in A-SHR was reduced in comparison with those of S-SHR or U-SHR, although BP in A-SHR was still higher than that in WKY. Both LV weight and the ratio of LV to BW also decreased in A-SHR compared with S-SHR or U-SHR. No difference in the LV collagen concentrations was observed among all SHR groups. These findings showed that ATN inhibition, ACE, and AT1 blockade could reduce the hypertrophy of myocytes in SHR. However, since the partial BP reduction did not produce changes in the remodeling of matrix tissue, it may be that both the reduction of BP and the inhibition of RAS play a crucial role in cardiac hypertrophy in SHR.


Cardiac Hypertrophy Angiotensin Converting Enzyme Activity Antisense ODNs Plasma Angiotensin Converting Enzyme Left Ventricular Weight 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baker KM, Booz GW, Dostal DE. 1992. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54:227–241.PubMedCrossRefGoogle Scholar
  2. 2.
    Adams MA, Bobik A, Korner PI. 1989. Differential development of vascular and cardiac hypertrophy in genetic hypertension: relation to sympathetic function. Hypertension 14:191–202.PubMedCrossRefGoogle Scholar
  3. 3.
    Korner P, Bobik A, Oddie C, Friberg P. 1993. Sympathoadrenal system is critical for structural changes in genetic hypertension. Hypertension 22:243–252.PubMedCrossRefGoogle Scholar
  4. 4.
    Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. 1994. Angiotensin-converting enzyme inhibitions improves cardiac function: role of bradykinin. Hypertension 23:411–418.PubMedCrossRefGoogle Scholar
  5. 5.
    Johnson CI. 1994. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 23:258–268.CrossRefGoogle Scholar
  6. 6.
    Schunkert H, Sadoshima J, Cornelius T, Kagaya Y, Weinberg EO, Izumo S, Riegger G, Lorell BH. 1995. Angiotensin II-induced growth responses in isolated adult rat hearts: evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 76:489–497.PubMedCrossRefGoogle Scholar
  7. 7.
    Suzuki J, Matsubara H, Urakami M, Inada M. 1993. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 73:439–447.PubMedCrossRefGoogle Scholar
  8. 8.
    Yoshida H, Kakuchi J, Guo DF, Furuta H, Iwai N, Jong R, Inagami T, Ichikawa I. 1992. Analysis of the evolution of angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine and human). Biochem Biophys Res Commun 186:1042–1049.PubMedCrossRefGoogle Scholar
  9. 9.
    Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine B, LeJemtel T, DeKock M. 1993. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88(pt 1):1602–1609.PubMedCrossRefGoogle Scholar
  10. 10.
    Ichiki T, Labosky PA, Shiota C, Okuyama S, Inagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BLM, Inagami T. 1995. Effects on blood pressure and exploratory behavior of mice lacking angiotensin II type-2 receptor. Nature 377:748–750.PubMedCrossRefGoogle Scholar
  11. 11.
    Hei L, Barsh GS, Pratt RE, Dzau VJ, Koblika BK. 1995. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 377:744–747.CrossRefGoogle Scholar
  12. 12.
    Jeunemaitre X, Soubrier F, Kotelevetsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P. 1992. Molecular basis of human hypertension: role of angiotensinogen. Cell 71:169–180.PubMedCrossRefGoogle Scholar
  13. 13.
    Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark A. 1994. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 330:1629–1633.PubMedCrossRefGoogle Scholar
  14. 14.
    Lynch KR, Peach MJ. 1991. Molecular biology of angiotensinogen. Hypertension 17:263–269.PubMedCrossRefGoogle Scholar
  15. 15.
    Panizo A, Pardo J, Hernandez M, Galindo MF, Cenarruzabeitia E, Diez J. 1995. Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. Am J Hypertens 8:815–822.PubMedCrossRefGoogle Scholar
  16. 16.
    Keeley FW, Elmoselhi A, Leenen FHH. 1992. Enalapril supresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol 262:H1013–H1021.PubMedGoogle Scholar
  17. 17.
    Makino N, Sugano M, Ohtsuka S, Sawada S. 1998. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases both the blood pressure and plasma angiotensin II levels. Hypertension 31:1166–1170.PubMedCrossRefGoogle Scholar
  18. 18.
    Widdop RE, Gardiner SM, Kemp PA, Benett T. 1993. Central administration of PD123319 or EXP-3174 inhibits effects of angiotensin II. Am J Physiol 264(Heart Circ Physiol 33):H117–H125.PubMedGoogle Scholar
  19. 19.
    Hayakari M, Kondoh Y, Ihumi H. 1978. A rapid and simple spectrophotometric assay of angiotensin-converting enzyme. Anal Biochem 84:361–369.PubMedCrossRefGoogle Scholar
  20. 20.
    Bergman I, Loxley R. 1961. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem 35:1961–1965.CrossRefGoogle Scholar
  21. 21.
    Makino N, Sugano M, Otsuka S, Hata T. 1997. Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension 30:796–802.PubMedCrossRefGoogle Scholar
  22. 22.
    Nagasawa K, Zimmermamm R, Munkel B, Linz W, Scholkens B, Schaper J. 1995. Extracellular matrix deposition in hypertensive hearts: antifibrotic effects of ramipril. Eur Hear J 16(Suppl C):33–37.CrossRefGoogle Scholar
  23. 23.
    Makino N, Sugano M, Hata T, Yanaga T. 1996. Chronic low dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy. Mol Cell Biochem 164:239–245.CrossRefGoogle Scholar
  24. 24.
    Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Linz W, Scholkens BA, Wiemer G, Unger T. 1993. Long-term low-dose angiotensin-converting enzyme inhibition treatment increases vascular cyclic guanine 3′,5′-monophospate. Hypertension 22:682–687.PubMedCrossRefGoogle Scholar
  25. 25.
    Kojima M, Shiojima I, Yamazaki T, Komuro I, Yunzeng Z, Ying W, Mizuni T, Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y. 1994. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocytes hypertrophy in vitro. Circulation 89:2204–2211.PubMedCrossRefGoogle Scholar
  26. 26.
    Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. 1995. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 92:10663–10667.PubMedCrossRefGoogle Scholar
  27. 27.
    Stoll M, Steckelings M, Paul M, Bottari SP, Metzger R, Unger T. 1995. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endotherial cells. J Clin Invest 95:651–657.PubMedCrossRefGoogle Scholar
  28. 28.
    Yamada T, Horiuchi M, Dzau V. 1996. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93:156–160.PubMedCrossRefGoogle Scholar
  29. 29.
    Wu GY, Wilson JM, Shalaby F, Grossman M, Shafritz DA, Wu CH. 1991. Receptor-mediated gene delivery in vivo. J Biol Chem 266:14338–14342.PubMedGoogle Scholar
  30. 30.
    Chowdhury NR, Wu CH, Wu GY, Yerneni PC, Bormmineni VR, Chowdhury JR. 1993. Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. J Biol Chem 268:11265–11271.PubMedGoogle Scholar
  31. 31.
    Lu XM, Fischman AJ, Jyawook SL, Hendricks K, Tompkins RG, Yarmush ML. 1994. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J Nucl Med 35:269–275.PubMedGoogle Scholar
  32. 32.
    Lodwick D, Kaiser MA, Harris J, Cumin F, Vincent M, Samani NJ. 1995. Analysis of the role of angiotensinogen in spontaneous hypertension. Hypertension 25:1245–1251.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Naoki Makino
    • 1
  • Masahiro Sugano
    • 1
  • Sachiyo Taguchi
    • 1
  1. 1.Department of Bioclimatology and Medicine, Medical Institute of BioregulationKyushu UniversityBeppuJapan

Personalised recommendations